Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial

NCT ID: NCT05973188

Last Updated: 2023-08-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 141 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-05-01
• Study Completion Date: 2024-06-30

Brief Summary

The investigators aimed to design this randomized control trial to compare rivaroxaban and apixaban with warfarin in Left ventricular thrombus resolution by

• Success rate of left ventricular thrombus resolution on follow up echocardiograms to be done at 1st, 3rd and 6th months after starting on these drugs.
• Compare the adverse events of each drug in terms of major bleeding and stroke on follow up.

Left ventricular thrombus (LVT) leads to thromboembolism in about 10-15% cases. Currently, guidelines recommended therapy for LVT is warfarin but treating LVT with warfarin is challenging due to

• Its narrow therapeutic window.
• Drug-drug and drug-food interaction.
• Frequently tested International normalization ratio (INR) and cost effectiveness especially in low to middle income countries.

In contrast Rivaroxaban and Apixaban has no drug-food or major drug-drug interaction and moreover it doesn't require frequent checks on INR and that's the reason Rivaroxaban and apixaban use in LVT is gaining traction over time but there is paucity of data both nationally and internationally. So further studies are required to evaluate the efficacy and safety of rivaroxaban and apixaban in comparison to warfarin in LVT, especially in low to middle income countries.

Detailed Description

1. TITLE:

Safety and efficacy of Rivaroxaban and Apixaban in comparison to Warfarin in Left ventricular clot- clinical trial

2. INTRODUCTION:

Left ventricular thrombus (LVT) is a known life threatening complication of myocardial systolic dysfunction leading to thromboembolism in about 10-15% cases1. The incidence of LVT has significantly decreased from 40% in pre-reperfusion era to 4% in reperfusion era but still it's a significant number to treat and minimize mortality and morbidities2.3. Up-to-date, guidelines recommended therapy for LVT is warfarin but due to its narrow therapeutic window, drug-drug and drug-food interaction, its use is challenging and cost effective, especially in low to middle income countries as it requires frequent checks on INR (International normalization ratio). In contrast Rivaroxaban has no drug-food or major drug-drug interaction and moreover it doesn't require frequent checks on INR and that's the reason Rivaroxaban use in LVT is gaining traction over time but there is paucity of data both nationally and internationally. Abdelnabi M et al. published the first RCT (randomized control trial, No-LVT trial) on Egyptian population and concluded that rivaroxaban is non inferior to warfarin in LVT but their sample was n=79 out of which rivaroxaban arm had 39 patients only with a power of 80%. Alcalai R et al,4 studied and compared warfarin and Apixaban in LV-thrombus and concluded that Apixaban is non inferior to warfarin in LV-thrombus but their sample size was very low to 17 patients in warfarin and 18 patients in apixaban group. So further studies are required to evaluate the safety and efficacy of rivaroxaban and apixaban in LVT specially in low to middle income countries where LVT management with warfarin is challenging because of narrowed therapeutic window and frequently testing INR. The investigators aimed to design this RCT to compare rivaroxaban and apixaban with warfarin in LVT in terms of safety and efficacy.

3. HYPOTHESIS:

Direct acting oral anticoagulation (rivaroxaban and apixaban) is non inferior to warfarin in LV thrombus resolution

4. MATERIALS AND METHODS: 4a. Study Design: It will be a prospective, randomized, open-label, parallel-group, noninferiority trial to evaluate the efficacy and safety of rivaroxaban and apixaban versus warfarin in the treatment of LVT.

4b. Study Settings: Peshawar Institute of Cardiology (PIC). 4c. Study Duration:

1 year

4d. Sample Size:

Type: Binary Yes/No Type Variable (e.g. response vs no response) Design: Parallel Group Objective: Non-inferiority

• Group 1 (Warfarin group): 48%
• Group 2 (Rivaroxaban group): 72%
• Group 3 (Apixaban group):

Non-inferiority criteria: 10% Power Level (%): 95% Acceptable Drop out %: 10% N per Group: 42 (not taking into account drop out). N per Group: 47 (accounting for drop out). Total N: 141 subjects to be recruited.

4e. Sampling Technique: Randomized and open label. The investigators will randomly assign first patient into group A that is control group (warfarin group) then next patient to group B (rivaroxaban group) and then next patient into group C (Apixaban group). The investigators will repeat the cycle to achieve the target sample size in each group. Patients will be randomized in group A, B and C in a ratio of 1:1:1, to either control group A (Warfarin group with dose adjusted, target INR 2-3), group B (Rivaroxaban 20mg QD) and group C (Apixaban 5mg BD (bis in die i.e. Twice a day) or 2.5mg BD if having two or more of the following, patients with age ≥80years and/or creatinin≥1.5 and/or body weight ≤60kg). LVT resolution will be assessed by blinded cardiologist via transthoracic echocardiogram at 1, 3 and 6 months' interval after starting on the respective regimen.

5. DATA COLLECTION PROCEDURE: On a preformed proforma.

6. DATA ANALYSIS PROCEDURE: Stata version 14.2 will be used for data analysis. Frequencies with percentages will be reported for categorical variables. Means with standard deviation (depending on the normality assumption) or Median with Interquartile range (if the normality assumption is not met). The chi2-Square test will be used to assess the statistical significance for categorical variables (Fischer Exact test will be used if the expected cell count is >= 5). Independent Student t-test will be used to assess the statistical significance of continuous variables.

P-value ≤0.05 will be considered significant.

Conditions

Left Ventricular Thrombus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A, warfarin group

Patients started on warfarin, dose will be adjusted according to patient target INR (2-3)

Group Type: ACTIVE_COMPARATOR

Warfarin

Intervention Type: DRUG

Anticoagulant

Group B, Rivaroxaban (Xcept)

Patients started on rivaroxaban 20mg single dose in 24hours

Group Type: EXPERIMENTAL

Rivaroxaban 20 MG Oral Tablet

Intervention Type: DRUG

Anticoagulant

Group C, Apixaban ( Apixaget)

Patients started on Apixaban 5mg or 2.5mg (12hours apart)

Group Type: EXPERIMENTAL

Apixaban 5mg or 2.5mg oral tablet

Intervention Type: DRUG

Anticoagulant

Interventions

Warfarin

Anticoagulant

Intervention Type: DRUG

Rivaroxaban 20 MG Oral Tablet

Anticoagulant

Intervention Type: DRUG

Apixaban 5mg or 2.5mg oral tablet

Anticoagulant

Intervention Type: DRUG

Other Intervention Names

Warfarin oral tablet; Xcept; Apixaget

Eligibility Criteria

Inclusion Criteria

• All hemodynamically stable patients with LV thrombus on echocardiogram after.

Exclusion Criteria

• Chronic Liver Disease (CLD) patients
• Creatinine clearance less than 15ml/min
• Recent Hemorrhagic stroke
• Thrombocytopenia, platelets <50k or anemia with baseline HB <9mg/dl
• Recent Major GI bleed
• History of atrial fibrillation and mitral stenosis
• History of deep vein thrombosis/pulmonary embolism and Patients already on anticoagulation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Getz Pharma

INDUSTRY

Sponsor Role: collaborator

Peshawar Institute of Cardiology

OTHER_GOV

Sponsor Role: lead

Responsible Party

Dr. Ihsan Ullah

Doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ihsan Ullah, MD

Role: PRINCIPAL_INVESTIGATOR

Peshawar Institute of Cardiology

Locations

Peshawar Institute of Cardiology

Peshawar, KPK, Pakistan

Site Status: RECRUITING

Countries

Pakistan

Central Contacts

Ihsan Ullah, MD

Role: CONTACT

dr.ihsanulla@gmail.com

+923365948083

Ali Raza, MRCP

Role: CONTACT

+923430978366

Facility Contacts

Ihsan Ullah, MD

Role: primary

dr.ihsanulla@gmail.com

+923365949083

Ali Raza, MBBS/MRCP

Role: backup

ali.raza@pic.edu.pk

+447833250880

Other Identifiers

IRC/23/09

Identifier Type: -

Identifier Source: org_study_id